Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1993 1
1994 1
1995 2
1997 11
1998 18
1999 32
2000 82
2001 151
2002 236
2003 290
2004 380
2005 340
2006 76
2007 106
2008 124
2009 154
2010 163
2011 172
2012 184
2013 230
2014 259
2015 302
2016 292
2017 266
2018 281
2019 386
2020 440
2021 403
2022 375
2023 339
2024 207

Text availability

Article attribute

Article type

Publication date

Search Results

5,679 results

Results by year

Filters applied: . Clear all
Page 1
Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway.
Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z, Xu P, Sun G, Xu J, Lv J, Xu Z. Zhang X, et al. Mol Cancer. 2019 Feb 4;18(1):20. doi: 10.1186/s12943-018-0935-5. Mol Cancer. 2019. PMID: 30717751 Free PMC article.
METHODS: We detected higher circNRIP1 expression in gastric cancer by performing RNA-seq analysis. We verified the tumour promotor role of circNRIP1 in gastric cancer cells through a series of biological function assays. ...CONCLUSIONS: We proved that circNRIP1 spon …
METHODS: We detected higher circNRIP1 expression in gastric cancer by performing RNA-seq analysis. We verified the tumour promotor ro …
CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.
Deng T, Shen P, Li A, Zhang Z, Yang H, Deng X, Peng X, Hu Z, Tang Z, Liu J, Hou R, Liu Z, Fang W. Deng T, et al. Theranostics. 2021 Jul 13;11(16):8112-8128. doi: 10.7150/thno.54961. eCollection 2021. Theranostics. 2021. PMID: 34335983 Free PMC article.
Finally, we observed that metformin, a new anti-cancer drug, can significantly induce CCDC65 to suppress ENO1-AKT1 complex-mediated cell proliferation and EMT signals and finally suppresses the malignant phenotypes of gastric cancer cells. Conclusion: These r …
Finally, we observed that metformin, a new anti-cancer drug, can significantly induce CCDC65 to suppress ENO1-AKT1 complex-med …
AKT1 Transcriptomic Landscape in Breast Cancer Cells.
George B, Gui B, Raguraman R, Paul AM, Nakshatri H, Pillai MR, Kumar R. George B, et al. Cells. 2022 Jul 25;11(15):2290. doi: 10.3390/cells11152290. Cells. 2022. PMID: 35892586 Free PMC article.
Overexpression and hyperactivation of the serine/threonine protein kinase B (AKT) pathway is one of the most common cellular events in breast cancer progression. However, the nature of AKT1-specific genome-wide transcriptomic alterations in breast cancer cell …
Overexpression and hyperactivation of the serine/threonine protein kinase B (AKT) pathway is one of the most common cellular events in breas …
PI3K/Akt signalling pathway and cancer.
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. Fresno Vara JA, et al. Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007. Cancer Treat Rev. 2004. PMID: 15023437 Review.
In recent years, it has been shown that PI3K/Akt signalling pathway components are frequently altered in human cancers. Cancer treatment by chemotherapy and gamma-irradiation kills target cells primarily by the induction of apoptosis. ...
In recent years, it has been shown that PI3K/Akt signalling pathway components are frequently altered in human cancers. Cancer …
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating beta-Catenin Signaling.
Gao SP, Kiliti AJ, Zhang K, Vasani N, Mao N, Jordan E, Wise HC, Shrestha Bhattarai T, Hu W, Dorso M, Rodrigues JA, Kim K, Hanrahan AJ, Razavi P, Carver B, Chandarlapaty S, Reis-Filho JS, Taylor BS, Solit DB. Gao SP, et al. Mol Cancer Res. 2021 Apr;19(4):573-584. doi: 10.1158/1541-7786.MCR-20-0623. Epub 2020 Dec 10. Mol Cancer Res. 2021. PMID: 33303690 Free PMC article.
Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 activation was not observed in breast cancer cells with PTEN loss or expression of an activating PIK3CA mutation, alterations which induc …
Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 acti …
Distinct functions of AKT isoforms in breast cancer: a comprehensive review.
Hinz N, Jücker M. Hinz N, et al. Cell Commun Signal. 2019 Nov 21;17(1):154. doi: 10.1186/s12964-019-0450-3. Cell Commun Signal. 2019. PMID: 31752925 Free PMC article. Review.
Breast cancer as the most common cancer entity in women, frequently shows alterations of the PI3K/AKT signaling. ...On the downside AKT1 decreases migration of breast cancer cells, for instance by regulating TSC2, palladin and EMT-proteins. ...
Breast cancer as the most common cancer entity in women, frequently shows alterations of the PI3K/AKT signaling. ...On the dow …
Evolutionary histories of breast cancer and related clones.
Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, Chigusa Y, Kawai M, Sawada M, Inoue T, Takeuchi Y, Maeda H, Baba S, Shiozawa Y, Saiki R, Nakagawa MM, Nannya Y, Ochi Y, Hirano T, Nakagawa T, Inagaki-Kawata Y, Aoki K, Hirata M, Nanki K, Matano M, Saito M, Suzuki E, Takada M, Kawashima M, Kawaguchi K, Chiba K, Shiraishi Y, Takita J, Miyano S, Mandai M, Sato T, Takeuchi K, Haga H, Toi M, Ogawa S. Nishimura T, et al. Nature. 2023 Aug;620(7974):607-614. doi: 10.1038/s41586-023-06333-9. Epub 2023 Jul 26. Nature. 2023. PMID: 37495687 Free PMC article.
However, our knowledge is still missing with regard to what additional driver events take place in what order, before one or more of these clones in normal tissues ultimately evolve to cancer. Here, using phylogenetic analyses of multiple microdissected samples from both …
However, our knowledge is still missing with regard to what additional driver events take place in what order, before one or more of these c …
AKT1(low) Quiescent Cancer Cells Promote Solid Tumor Growth.
Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S. Alves CP, et al. Mol Cancer Ther. 2018 Jan;17(1):254-263. doi: 10.1158/1535-7163.MCT-16-0868. Epub 2017 Oct 20. Mol Cancer Ther. 2018. PMID: 29054988 Free PMC article.
Here, we selectively disrupt the ability of rapidly proliferating cancer cells to spawn AKT1(low) daughter cells that are rare, slowly proliferating, tumor-initiating, and chemotherapy-resistant, using beta1-integrin activation and the AKT1-E17K-mutant oncopr …
Here, we selectively disrupt the ability of rapidly proliferating cancer cells to spawn AKT1(low) daughter cells that are rare …
Accelerating Discovery of Functional Mutant Alleles in Cancer.
Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS. Chang MT, et al. Cancer Discov. 2018 Feb;8(2):174-183. doi: 10.1158/2159-8290.CD-17-0321. Epub 2017 Dec 15. Cancer Discov. 2018. PMID: 29247016 Free PMC article.
Most mutations in cancer are rare, which complicates the identification of therapeutically significant mutations and thus limits the clinical impact of genomic profiling in patients with cancer. ...Sharing prospective genomic data will accelerate hotspot identificat …
Most mutations in cancer are rare, which complicates the identification of therapeutically significant mutations and thus limits the …
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M, Chi KN, Wyatt AW. Herberts C, et al. Eur Urol. 2020 Dec;78(6):834-844. doi: 10.1016/j.eururo.2020.04.058. Epub 2020 May 22. Eur Urol. 2020. PMID: 32451180
BACKGROUND: Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic castration-resistant prostate cancer (mCRPC), but are linked to activation of phosphatidylinositol 3-kinase (PI3K) signalling and sensitivity to pathway inhibitors in other c …
BACKGROUND: Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic castration-resistant prostate cancer …
5,679 results